Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | S100A4 | P26447 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585545 | 0.83 | ACHE (0.53) | ACHES100A4PARP1MAPTRECQL | |
| SCHEMBL2060410 | 0.79 | S100A4 (0.47) | ACHES100A4PARP1MAPTRECQL | |
| SCHEMBL12087018 | 0.78 | HTR2A (0.42) | ACHEPARP1PDPK1PARP10PARP11 | |
| SCHEMBL376278 | 0.78 | PNMT (0.47) | ACHES100A4MAPTPNMTALDH1A1 | |
| SCHEMBL4621603 | 0.76 | ACHE (0.56) | ACHES100A4MAPTRECQLKMT2A | |
| SCHEMBL12087016 | 0.75 | HTR2A (0.40) | PARP1PDPK1PARP10PARP11MAPT | |
| SCHEMBL7581608 | 0.74 | PARP1 (0.57) | ACHES100A4PARP1PDPK1PARP10 | |
| SCHEMBL4694280 | 0.74 | TDP2 (0.59) | ACHES100A4MAPTRECQLKMT2A | |
| SCHEMBL19308811 | 0.74 | PARP10 (0.53) | PARP1PDPK1PARP10PARP11TUBB4A | |
| SCHEMBL10566080 | 0.73 | ACHE (0.53) | ACHES100A4MAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4298092-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| CN-116829550-A | Pyrimidine-2-ylsulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022180136-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-01 | — | — | WO | disclosed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | AMGEN INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | NQO1, NQO2, UGT1A1 | ACHE 2495/4885S100A4 4089/4885PARP1 479/4885 |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | ACHE 4868/4885S100A4 2116/4885PARP1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.